OSUR ORASURE TECHNOLOGIES INC
Price Chart
Executive Summary
OraSure Technologies reported a significant decline in Q4 and full-year 2025 revenue, down 29% and 38% respectively, driven by steep drops in its core diagnostics and sample management businesses. Despite the poor financial performance, the company highlighted new FDA submissions for a Chlamydia/Gonorrhea self-test and a urine collection device, and maintained a $40 million share buyback program. The filing presents a mixed picture of deteriorating fundamentals offset by future growth initiatives.
Key Financial Metrics
Actionable Insight
The stock may face downward pressure due to the significant revenue decline and sustained losses. However, traders should monitor the progress of the two new FDA submissions as potential catalysts for future growth. The continued share buyback provides some support, but the weak guidance for Q1 2026 suggests the turnaround will take time.
Key Facts
- Q4 2025 revenue was $26.8 million, down 29% YoY; full-year revenue was $115 million, down 38% YoY.
- Core business revenue (excluding COVID-19) declined 22% YoY in Q4 and 14% for the full year.
- GAAP net loss was $19.3 million for Q4 and $68.7 million for the full year.
- Company submitted two new applications to the FDA in December 2025 for a rapid molecular self-test for Chlamydia/Gonorrhea and a Colli-Pee at-home urine collection device.
- Company deployed $5 million to repurchase 1.9 million shares in Q4 and has $25 million remaining on its $40 million buyback program.
- Q1 2026 revenue guidance is $26-$29 million, indicating no immediate recovery.
Financial Impact
Revenue declined by $10.7 million in Q4 and $70.8 million for the full year, with a net loss of $68.7 million for the year.
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Core Business | $26.7M | -22.0% |
| Diagnostics | $15.1M | -20.0% |
| Sample Management Solutions | $9.1M | -39.0% |
Risk Factors
- Continued revenue decline in core business segments.
- Failure to gain FDA approval for new product submissions.
- High operating losses may deplete cash reserves despite strong balance sheet.
Market Snapshot
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001116463-26-000009 |
| Exhibit: exhibit992_q4-25investor.htm | 0001116463-26-000009 |
| Document: osur-20260225.htm | 0001116463-26-000009 |
| Document: 0001116463-26-000009-index-headers.html | 0001116463-26-000009 |
| Document: 0001116463-26-000009-index.html | 0001116463-26-000009 |
| Document: 0001116463-26-000009.txt | 0001116463-26-000009 |
| CONTEXT: Previous Earnings (2026-02-25) | 0001116463-26-000009 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
today
|
Institutional Cluster
| $4.18 awaiting T+1 | awaiting T+1 | — | $4.18 (+0.12%) |
|
Jun 3, 2026
9d ago
|
8-K
| $4.17 $4.04 | ▼ −3.12% | ▼ −0.52% | $4.18 (+0.24%) |
|
May 6, 2026
5w ago
|
8-K
| $3.13 $3.06 | ▲ +2.24% | ▲ +3.07% | $4.18 (−33.55%) |
|
Apr 22, 2026
7w ago
|
Press Release
| $3.05 $3.00 | ▲ +1.64% | ▲ +2.42% | $4.18 (−37.05%) |
|
Apr 17, 2026
8w ago
|
DEFA14A
| $3.16 $3.19 | ▲ +0.95% | ▲ +1.14% | $4.18 (+32.28%) |
|
Apr 17, 2026
8w ago
|
DEFA14A
| $3.16 $3.19 | ▲ +0.95% | ▲ +1.14% | $4.18 (+32.28%) |
|
Apr 17, 2026
8w ago
|
8-K
| $3.16 $3.19 | ▲ +0.95% | ▲ +1.14% | $4.18 (+32.28%) |
|
Mar 20, 2026
12w ago
|
Insider Cluster
| $2.95 $3.08 | ▲ +4.41% | ▲ +3.30% | $4.18 (+41.69%) |
|
Mar 17, 2026
12w ago
|
DEFA14A
| $2.90 $2.91 | ▲ +0.34% | ▲ +0.61% | $4.18 (+44.14%) |
|
Mar 13, 2026
13w ago
|
Insider Cluster
| $2.97 $3.13 | ▲ +5.39% | ▲ +4.36% | $4.18 (+40.74%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access